Prothena Corp Public (PRTA) Current Leases (2019 - 2026)
Prothena Corp Public (PRTA) posted quarterly Current Leases of $2.9 million for Q1 2026, up 10.08% year-over-year from $2.6 million in Q1 2025, and little changed quarter-over-quarter from $2.9 million in Q4 2025.
Analysis
Prothena Corp Public (PRTA) Current Leases (2019 - 2026) Analysis & Trends
Prothena Corp Public's Current Leases history runs 8 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Current Leases rose 10.08% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 10.08% YoY), while the FY2025 annual figure was $2.9 million, up 10.57% from the prior year.
- Current Leases for Q1 2026 stood at $2.9 million, roughly flat from $2.9 million in the prior quarter.
- The five-year high for Current Leases was $6.5 million in Q4 2022, with the low at $1.1 million in Q4 2023.
- The 5-year median for Current Leases is $2.9 million (2025), against an average of $3.6 million.
- The sharpest annual moves came in 2023 and 2024: Current Leases sank 82.79% in 2023, then surged 134.29% in 2024.
- Prothena Corp Public's Current Leases stood at $6.5 million in 2022, then tumbled by 82.79% to $1.1 million in 2023, then soared by 134.29% to $2.6 million in 2024, then grew by 10.57% to $2.9 million in 2025, then climbed by 0.24% to $2.9 million in 2026.
- Business Quant data shows PRTA's Current Leases at $2.9 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Prothena Corp Public | 509.98 Mn | 221.78 Mn | - | 2.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.96 Mn |
| Mar 31, 2026 | 2.89 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.88 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.82 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 4.89 Mn |
| Dec 31, 2022 | 6.47 Mn |
| Sep 30, 2022 | 6.39 Mn |
| Jun 30, 2022 | 6.30 Mn |
| Mar 31, 2022 | 6.05 Mn |
| Dec 31, 2021 | 5.94 Mn |
| Sep 30, 2021 | 5.83 Mn |